In a 56-year-old female with atrial fibrillation, hypertension, and a thyroid nodule scheduled for subtotal thyroidectomy in three weeks, who is on chronic warfarin with an INR of 2.3 and has no history of coronary artery disease, peripheral vascular disease, or stroke, what perioperative anticoagulation strategy should be recommended?

Perioperative Anticoagulation Recommendation

For this 56-year-old woman with atrial fibrillation on warfarin undergoing subtotal thyroidectomy, you should stop warfarin 5 days before surgery without heparin bridging, and resume warfarin 12-24 hours postoperatively once adequate hemostasis is achieved.

Risk Stratification

Thromboembolic Risk Assessment

This patient has a low thromboembolic risk based on her clinical profile 1, 2:

• CHA2DS2-VASc score = 2 (1 point for female sex, 1 point for hypertension) 1, 2
• No history of stroke, TIA, or systemic embolism 2
• No mechanical heart valve 1, 2
• According to the 2024 AHA/ACC guidelines, a CHA2DS2-VASc score of 1-4 without prior stroke history is classified as low thromboembolic risk (annual risk <4%) 1
• The 2022 CHEST guidelines similarly classify CHA2DS2-VASc ≤4 or CHADS2 ≤2 as low risk 2

Surgical Bleeding Risk

Thyroidectomy is considered a moderate to high bleeding risk procedure due to:

• Large exposed vascular surgical field 1
• Risk of hematoma formation that can compromise the airway 1
• Proximity to critical neck structures 1

Perioperative Management Strategy

Warfarin Discontinuation

Stop warfarin 5 days (approximately 5 half-lives) before surgery 1, 2:

• Warfarin has a half-life of 36-48 hours 1
• Stopping 5 days preoperatively allows the INR to normalize to <1.5 1, 2
• The duration of anticoagulation effect persists for approximately 2-5 days after discontinuation 3

No Heparin Bridging Required

Do NOT use heparin bridging in this patient 1, 2:

• Bridging is not recommended for low thromboembolic risk patients (CHA2DS2-VASc 1-4 without prior stroke) 1, 2
• Meta-analyses demonstrate that bridging increases bleeding risk without reducing thromboembolic events in low-risk patients 1
• The short perioperative period off anticoagulation (5-7 days total) poses minimal thrombotic risk in this population 2
• A systematic review found recurrent thromboembolism rates remain low regardless of bridging strategy in low-risk patients, while bridging significantly increased bleeding 1

Postoperative Resumption

Resume warfarin 12-24 hours after surgery once adequate surgical hemostasis is confirmed 1, 2:

• Earlier resumption (within 24 hours) is appropriate for low bleeding risk once hemostasis is secure 1
• For thyroidectomy specifically, ensure no evidence of neck hematoma or bleeding before restarting 1
• No loading dose is needed; resume the patient's usual maintenance dose 3
• Recheck INR in 3-5 days and adjust dosing to achieve target INR 2.0-3.0 3

Critical Pitfalls to Avoid

Common Errors

• Do not bridge with heparin or LMWH - this substantially increases bleeding risk without benefit in low-risk AF patients 1, 2
• Do not stop warfarin too close to surgery - stopping only 2-3 days before may leave residual anticoagulant effect 1
• Do not delay warfarin resumption excessively - prolonged interruptions beyond 7-10 days increase stroke risk, and multiple interruptions are associated with over twice the stroke risk 4
• Do not restart warfarin if there are signs of ongoing bleeding or surgical concerns about hemostasis 1

Monitoring Considerations

• Check INR 1-2 days before surgery to confirm normalization (target <1.5) 1, 2
• If INR remains elevated close to surgery, consider vitamin K 1-2.5 mg orally to expedite reversal 1
• Avoid emergency reversal agents (prothrombin complex concentrates) unless urgent surgery is required, as time-based reversal is always preferred 1

Timeline Summary

3 weeks before surgery (now):

• Continue warfarin at current dose 3

5 days before surgery:

• Stop warfarin 1, 2

1-2 days before surgery:

• Check INR to confirm <1.5 1, 2

Day of surgery:

• Proceed with thyroidectomy 1

12-24 hours postoperatively:

• Resume warfarin at usual maintenance dose if hemostasis is adequate 1, 2

3-5 days after resuming:

• Recheck INR and adjust dose to maintain therapeutic range 2.0-3.0 3

This approach balances stroke prevention with bleeding risk, following the most current evidence-based guidelines for perioperative anticoagulation management in low-risk atrial fibrillation patients 1, 2.